Prosecution Insights
Last updated: November 20, 2026
Application No. 18/792,994

AIRWAY BASAL CELL ENGRAFTMENT METHODS

Final Rejection §102§103
Filed
Aug 02, 2024
Priority
Aug 02, 2023 — provisional 63/530,370
Examiner
ABUZEINEH, HANAN ISAM
Art Unit
1633
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Trustees of Boston University
OA Round
4 (Final)
52%
Grant Probability
Moderate
5-6
OA Rounds
1y 7m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 52% of resolved cases
52%
Career Allowance Rate
44 granted / 84 resolved
-7.6% vs TC avg
Strong +54% interview lift
Without
With
+54.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 11m
Avg Prosecution
20 currently pending
Career history
108
Total Applications
across all art units

Statute-Specific Performance

§101
2.2%
-37.8% vs TC avg
§103
46.4%
+6.4% vs TC avg
§102
17.4%
-22.6% vs TC avg
§112
27.1%
-12.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 84 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicants’ response and amendments filed on 06/26/2026 are acknowledged and have been entered. Election/Restrictions Applicant has previously elected with traverse Group I, drawn to a method of engrafting airway basal cells into the respiratory tract of a subject in need thereof, the method comprising removing epithelial cells from the respiratory tract and administering airway basal cells to the respiratory tract. Claims 1-6, 8-20, 22-29, and 31-33 were pending and under consideration. Claim 9 is currently amended. Claims 1-6, 8-20, 22-29, and 31-33 are under examination in the instant application. Status of Prior Rejections/Response to Arguments RE: Rejection of claim 9 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph: Applicants have amended claim 9 to depend from claim 2, such that there is sufficient antecedent basis for for the limitation “the chemical agent” in the claim. The rejection is therefore withdrawn. RE: Rejection of claims 1, 8-13, 15-18, 22-32 under 35 U.S.C. 102(a)(1) as being anticipated by Ma et al.: Applicants have traversed the rejection asserting that Ma does not teach that steps (a) and (b) of independent claims 1, 28 and 29 are performed on the same subject. Applicants argue that Ma et al. discloses brushing off epithelial cells from human lungs, while the airway basal cells are transplanted into mouse lung parenchyma. This is not persuasive because Ma et al. does also clearly teach in the Abstract showing that a rare population of SOX9+ basal cells (BCs) located at airway epithelium rugae can regenerate adult human lung. Human SOX9+ BCs can be readily isolated by bronchoscopic brushing and indefinitely expanded in feeder-free condition to regenerate adult human lung. Ma et al. further discloses “Most importantly, for the first time we explored the clinical feasibility of autologous SOX9+ BC transplantation to treat two patients with chronic lung diseases.”, which is highly consistent with the observation on the mouse model (page 268, column 1, last paragraph). Applicants further argue that the tissue disruption of Ma is in the trachea, e.g., the epithelial cell removed are not in at least one bronchus and/or at least one bronchiole, as instantly claimed. This is not persuasive, because Ma et al. does clearly teach in the Abstract brushing the bronchiolar epithelium. Applicant's arguments filed on 06/26/2026 have been fully considered but they are not persuasive. The rejection is therefore maintained. RE: Rejection of claims 1-6 under 35 U.S.C. 103 as being unpatentable over Ma et al., in view of Farrow et al.: Applicants have traversed the rejection asserting that Farrow does nothing to relieve the deficiencies of Ma Applicants have not addressed the teachings of Farrow et al. for the reasons it was cited for. The rejection is therefore maintained. RE: Rejection of claims1, 14, 19-20 under 35 U.S.C. 103 as being unpatentable over Ma et al., in view of HAWKINS et al.: Applicants have traversed the rejection asserting that HAWKINS does nothing to relieve the deficiencies of Ma et al. Applicants have not addressed the teachings of HAWKINS et al. for the reasons it was cited for. The rejection is therefore maintained. RE: Rejection of claim 33 under 35 U.S.C. 103 as being unpatentable over Ma et al., in view of Dimmer et al. (US9662171B2): Applicants have traversed the rejection asserting that Dimmer et al. does nothing to relieve the deficiencies of Ma et al. Applicants have not addressed the teachings of Dimmer et al. for the reasons it was cited for. The rejection is therefore maintained. New/Maintained Rejections Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim(s) 1, 8-13, 15-18, 22-32 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Ma et al. (Ma et al., "Regeneration of functional alveoli by adult human SOX9+ airway basal cell transplantation". Protein & Cell, Volume 9, Issue 3, March 2018, Pages 267–282). Regarding claim 1, Ma et al. teaches a method of engrafting airway basal cells into the respiratory tract of a subject in need thereof (Abstract and page 271, column 2, paragraph 1 and page 277, column 1, paragraph 3, Methods), the method comprising:(a) removing epithelial cells from the respiratory tract of the subject (Abstract and page 268, column 2, paragraph 1, lines 1-5), wherein the epithelial cells are removed in at least one bronchus and/or at least one bronchiole of the respiratory tract (page 268, column 2, paragraph 1, lines 4-7); and (b) then administering airway basal cells to the respiratory tract of the subject (Abstract and page 271, column 1, paragraph 2, lines 1-5). Regarding claim 8: Following discussion of claim 1 above, Ma et al. teaches the airway basal cells are administered to at least one bronchiole of the respiratory tract (Abstract and page 271, column 1, paragraph 2, lines 29-32). Regarding claim 9: Following discussion of claim 1 above, Ma et al. teaches that the airway basal cells are administered using a bronchoscope (page 277, column 1, paragraph 3, Methods). Regarding claim 10: Following discussion of claim 1 above, Ma et al. teaches that the cells are obtained from a biopsy (paragraphs 0114 and 0314). This reads on the airway basal cells are primary cells (Abstract and Figure 3, page 272). Regarding claim 11: Following discussion of claim 1 above, Ma et al. teaches that the basal cells are generated from induced pluripotent stem cells (page 268, column 1, paragraph 1, lines 10-14). Regarding claim 12: Following discussion of claim 1 above, Ma et al. teaches that the airway basal cells (BCs) express one or more markers selected from the group consisting of: Nkx2-1; tumor protein 63 (TP63); cytoskeletal protein keratin 5 (KRT5) (page 268, column 2, paragraph 1, lines 10-17). Regarding claim 13: Following discussion of claim 1 above, Ma et al. teaches that the airway basal cells are autologous to the subject (page 268, column 1, paragraph 1, lines 10-14 and paragraph 3). Regarding claim 15: Following discussion of claim 1 above, Ma et al. teaches that the cells are derived from a healthy subject (page 270, column 1, last paragraph). Regarding claim 16: Following discussion of claim 1 above, Ma et al. teaches that the cells are derived from a subject that has a respiratory tract disease or a respiratory tract injury (page 270, column 1, last paragraph). Regarding claim 17: Following discussion of claim 1 above, Ma et al. teaches that the respiratory tract disease is chronic obstructive pulmonary disease (COPD) (page 270, column 1, last paragraph). Regarding claim 18: Following discussion of claim 1 above, Ma et al. teaches that the respiratory tract injury is associated with a surgery (page 270, column 1, paragraph 1). Regarding claim 22: Following discussion of claim 1 above, Ma et al. teaches that the engrafted airway basal cells reconstitute the tissue-resident airway basal stem cell compartment in the respiratory tract of the subject (page 268, column 1, last paragraph). Regarding claim 23: Following discussion of claim 1 above, Ma et al. teaches that the engrafted airway basal cells comprise at least 10% of the epithelium in the respiratory tract of the subject after the engraftment (page 268, column 2, paragraphs 1-2). Regarding claim 24: Following discussion of claim 1 above, Ma et al. teaches that the engrafted airway basal cells persist for at least 2 years following the engraftment (Figure 7, page 276). Regarding claims 25-26: Following discussion of claim 1 above, Ma et al. teaches that the engrafted airway basal cells exhibit self- renewal and/or multipotent differentiation capacity for at least 2 years following the engraftment, wherein the multipotent differentiation capacity comprises basal cells (page 271, column 1, paragraph 2). Regarding claim 27: Following discussion of claim 1 above, Ma et al. teaches that the engrafted airway basal cells exhibit a transcriptome that is at least 80% identical to the transcriptome of endogenous airway epithelium cells (Figure 1, page 268, column 2, paragraph 2). Regarding claim 28: Following discussion of claim 1 above, Ma et al. teaches a method of treating a respiratory tract disease, the method comprising:(a) removing epithelial cells from the respiratory tract of a subject in need thereof, wherein the epithelial cells are removed in at least one bronchus and/or at least one bronchiole of the respiratory tract; and(b) then administering an effective amount of airway basal cells to the respiratory tract of the subject, wherein the respiratory tract disease is COPD (Abstract and page 271, column 2, paragraph 1 and page 277, column 1, paragraph 3, Methods, page 271, column 1, paragraph 2, lines 1-5, and page 270, column 1, last paragraph). Regarding claim 29: Following discussion of claim 1 above, Ma et al. teaches a method of treating a respiratory tract injury, the method comprising:(a) removing epithelial cells from the respiratory tract of a subject in need thereof, wherein the epithelial cells are removed in at least one bronchus and/or at least one bronchiole of the respiratory tract; and(b) then administering an effective amount of airway basal cells to the respiratory tract of the subject; wherein the respiratory tract injury is associated with surgery (Abstract and page 271, column 2, paragraph 1 and page 277, column 1, paragraph 3, Methods, page 271, column 1, paragraph 2, lines 1-5, and page 270, column 1, paragraph 1). Regarding claim 31: Following discussion of claim 18 above, Ma et al. teaches that the surgery is lung lobectomy (page 270, column 1, paragraph 1). Regarding claim 32: Following discussion of claim 29 above, Ma et al. teaches that the surgery is lung lobectomy (page 270, column 1, paragraph 1). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 1-6 is/are rejected under 35 U.S.C. 103 as being unpatentable over Ma et al. (Ma et al., "Regeneration of functional alveoli by adult human SOX9+ airway basal cell transplantation". Protein & Cell, Volume 9, Issue 3, March 2018, Pages 267–282), in view of Farrow et al. (Farrow et al., “Epithelial disruption: a new paradigm enabling human airway stem cell transplantation”. Stem Cell Res Ther 9, 153 (2018), pages 1-8). Regarding claim 1, the teachings of Ma et al. are set forth in detail above. Regarding claim 2: Following discussion of claim 1 above, Ma et al. fails to teach that the epithelial cells are removed from the respiratory tract using a chemical agent. However, Farrow et al. teaches that 4 μL of 2% the agent polidocanol (PDOC) in phosphate-buffered saline was administered to the nasal airway of mice to disrupt the epithelium (Abstract, Methods). Farrow et al. further teaches that PDOC treatment denudes the nasal or tracheal epithelium but spares basal cells (page 6, column 2, paragraph 2, lines 1-2). Polidocanol reads on a chemical agent. Farrow et al. also teaches that disrupting the epithelial cell layer using the agent polidocanol (PDOC) would facilitate effective transplantation of cultured stem cells in mouse nasal airways (Abstract, Background). Therefore, it would have been prima facie obvious to one of the ordinary skills in the art before the effective filing date of the claimed invention to have modified the method of Ma et al. and administered PDOC to the bronchial epithelium instead of using a bronchoscope with a reasonable expectation of success. One would have been motivated to have done so for the purpose of removing the epithelium cells from the respiratory tract before administering the airway basal cells with predictable results. Regarding claim 3: Following discussion of claim 2 above, Polidocanol is known in the art as a synthetic, non-ionic detergent. Regarding claim 4: Following discussion of claim 2 above, Farrow et al. teaches that 4 μL of 2% the agent polidocanol (PDOC) in phosphate-buffered saline was administered to the nasal airway of mice to disrupt the epithelium (Abstract, Methods). Regarding claim 5: Following discussion of claim 2 above, Farrow et al. teaches that 4 μL of 2% the agent polidocanol (PDOC) in phosphate-buffered saline was administered to the nasal airway of mice to disrupt the epithelium (Abstract, Methods). Regarding claim 6: Following discussion of claim 1 above, Farrow et al. further teaches that at 2 or 24 h after PDOC treatment, human airway basal cells were transplanted into the animals (Abstract, Methods). Claim(s) 1, 14, 19-20 is/are rejected under 35 U.S.C. 103 as being unpatentable over Ma et al. (Ma et al., "Regeneration of functional alveoli by adult human SOX9+ airway basal cell transplantation". Protein & Cell, Volume 9, Issue 3, March 2018, Pages 267–282), in view of HAWKINS et al. (the US Patent Application Publication US20210254016A1, filed on 02/19/2021, and published on 08/19/2021). Regarding claim 1, the teachings of Ma et al. are set forth in detail above. Regarding claim 14: Following discussion of claim 1 above, Ma et al. fails to teach that the airway basal cells are engineered to reduce or prevent expression of at least one major histocompatibility complex (MHC) polypeptide to reduce immunogenicity of the airway basal cells. However, HAWKINS et al. teaches that the airway basal cells (BCs) are genetically modified in which the cells comprise a genome that has been manipulated, e.g., by mutation, such as site-directed mutation (paragraphs 0049 and 0333). Site-directed mutation is a mutation that can reduce MHC expression. HAWKINS et al. further teaches in paragraphs 0115 and 0333 that such mutations result in a change in gene or protein expression relative to an un-modified cell. Introduction of RNA can transiently promote expression of a foreign or heterologous product, as can the introduction of a vector that does not integrate or replicate within the cell and such modification is to reduce the risk of engraftment rejection or immunogenicity of the cells. Therefore, it would have been prima facie obvious to one of the ordinary skills in the art before the effective filing date of the claimed invention to have modified the airway basal cells in the method of Ma et al. to reduce or prevent expression of MHC with a reasonable expectation of success. One would have been motivated to have done so in order to reduce immunogenicity of the airway basal cells as taught by HAWKINS et al. Regarding claims 19 and 20: Following discussion of claim 1 above, HAWKINS et al. teaches mutations of the CFTR gene affecting chloride ion channel function leads to dysregulation of epithelial fluid transport in the lung, pancreas and other organs, resulting in cystic fibrosis (paragraph 0241). HAWKINS et al. further teaches that the airway basal cell line is genetically modified to correct a genetic lesion or mutation in the CFTR gene that causes cystic fibrosis (paragraph 0330). Correcting a mutation in the CFTR gene that causes cystic fibrosis reads on expressing at least one functional polypeptide that is dysfunctional in a respiratory tract disease as recited in claim 19 and on expressing functional CFTR polypeptide as recited in claim 20. Additionally, HAWKINS et al. teaches that mutations in DNAH5 have been associated with primary ciliary dyskinesia (PCD) and that the airway basal cells described herein are genetically modified to correct a DNAH5 mutation (paragraph 0243, line 3 and last 2 lines). Correcting a mutation in the DNAH5 gene that causes primary ciliary dyskinesia reads on expressing functional DNAH5 polypeptide. Claim(s) 33 is rejected under 35 U.S.C. 103 as being unpatentable over Ma et al. (Ma et al., "Regeneration of functional alveoli by adult human SOX9+ airway basal cell transplantation". Protein & Cell, Volume 9, Issue 3, March 2018, Pages 267–282), in view of Dimmer et al. (US9662171B2, issued on 05/30/2017). Regarding claim 33, Ma et al. teaches a method of engrafting airway basal cells into the respiratory tract of a subject in need thereof, the method comprising:(a) removing epithelial cells from the respiratory tract, wherein the epithelial cells are removed in at least one bronchus of the respiratory tract of the subject and (b) then administering airway basal cells to the respiratory tract of the subject (Abstract and page 271, column 2, paragraph 1 and page 277, column 1, paragraph 3, Methods and page 271, column 1, paragraph 2, lines 1-5). However, Dimmer et al. teaches using bronchial thermoplasty to remove cells in the inner lining of the airway wall, such as the epithelium. Dimmer et al. specifically teaches that heat can be concentrated in the inner lining (e.g., the epithelium) of the airway wall (column 21, lines 66-67 and column 22, lines 1-2). Dimmer et al. also teaches that treatments for pulmonary diseases, such as COPD and asthma, such as bronchial thermoplasty, involve destroying cells by ablating the airway wall in a multitude of bronchial branches within the lung (column 3, lines 44- 48). Bronchial thermoplasty uses heat to reduce excess airway smooth muscle tissue, which minimizes the airway constriction that takes place during an asthma attack. This reads on removing the epithelial cells from the respiratory tract using bronchial thermoplasty. Therefore, it would have been prima facie obvious to one of the ordinary skills in the art before the effective filing date of the claimed invention to have modified the method of Ma et al. and removed the epithelium using bronchial thermoplasty to isolate the epithelial cells from the respiratory tract before administering the airway basal cells with a reasonable expectation of success. One would have been motivated to have done so to reduce excess airway smooth muscle tissue which minimizes the airway constriction and facilitate effective transplantation and enragement of the airway basal cells in the respiratory tract of said subject. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to HANAN ISAM ABUZEINEH whose telephone number is (571)272-9596. The examiner can normally be reached Mon- Fri 8:30-5:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, CHRISTOPHER BABIC can be reached at (571)272-8507. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Hanan Isam Abuzeineh /H.I.A./Examiner, Art Unit 1633 /CHRISTOPHER M BABIC/Supervisory Patent Examiner, Art Unit 1633
Read full office action

Prosecution Timeline

Show 2 earlier events
Aug 05, 2025
Response Filed
Sep 11, 2025
Final Rejection mailed — §102, §103
Dec 10, 2025
Response after Non-Final Action
Feb 06, 2026
Request for Continued Examination
Feb 11, 2026
Response after Non-Final Action
Mar 26, 2026
Non-Final Rejection mailed — §102, §103
Jun 26, 2026
Response Filed
Nov 05, 2026
Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12799503
COMPOSITIONS AND METHODS FOR TREATING NGYL1 DEFICIENCY
3y 0m to grant Granted Nov 17, 2026
Patent 12773452
COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING CD70 SPECIFIC FUSION PROTEINS
3y 11m to grant Granted Oct 27, 2026
Patent 12734196
METHODS OF DIFFERENTIATING NEURAL CELLS AND RELATED COMPOSITIONS AND METHODS OF USE
4y 2m to grant Granted Sep 15, 2026
Patent 12716057
METHOD FOR CULTURING GYNAECOLOGICAL TUMOUR PRIMARY CELLS AND MATCHING CULTURE MEDIUM
4y 1m to grant Granted Aug 25, 2026
Patent 12702688
Stable Frozen Virus Formulation
5y 11m to grant Granted Aug 11, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
52%
Grant Probability
99%
With Interview (+54.1%)
3y 11m (~1y 7m remaining)
Median Time to Grant
High
PTA Risk
Based on 84 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month